Tuberculosis, Alcohol, and Lung Comorbidities (TALC) Study
Grant Title: The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV
The Tuberculosis, Alcohol, and Lung Comorbidities (TALC) Study will investigate hazardous drinking as a modifiable risk factor for post-TB lung disease in PWH over the course of an 18-month observational study of 200 PWH completing pulmonary TB treatment in Mbarara, Uganda. The study will evaluate the following post-TB lung disease outcomes: functional exercise capacity (primary outcome assessed by 6-minute walk distance), lung physiology (pulmonary function tests), anatomy (CT scan), and lung infections. The primary exposure is past-year hazardous drinking. Secondary alcohol measures will include 30- day Timeline Followback (calendar-based method of alcohol use recall) and phosphatidylethanol (PEth; a biomarker of recent alcohol use). The study’s primary aim (Aim 1a) is to determine the relationship between past-year hazardous drinking and post-TB lung disease. Aim 1b will assess the association of past-month heavy drinking and post-TB lung disease progression over time. Aim 1c will explore whether smoking modifies the association of past- month heavy drinking and post-TB lung disease progression over time. In Aim 2, the study team will qualitatively evaluate factors that can improve tailoring of pharmaco-behavioral alcohol and smoking interventions in PWH receiving TB treatment.
Kaku So-Armah, PhD
Boston University Chobanian & Avedisian School of Medicine
Sarah Rossi, MPH
Research Project Manager
Boston Medical Center
Study Staff and Investigators:
Click here to view information for additional study staff and investigators.